Dr. Catenacci on Study of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer

Daniel Catenacci, MD
Published: Wednesday, Feb 28, 2018



Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

The anti-HER2 monoclonal antibody, margetuximab, is being studied in combination with pembrolizumab as a treatment for patients with advanced HER2-positive GEJ or gastric adenocarcinoma. Margetuximab has an optimized Fc domain to increase affinity for activating CD16A-F allele, says Catenacci, and preclinical data suggests activity in HER2-positive patients. Additionally, pembrolizumab has demonstrated durable responses in this population.

In a phase Ib study assessing the safety and toxicity of the combination, there were no unforeseen events of toxicities. Catenacci says that most of the toxicities were attributed to the anti–PD-1 agent pembrolizumab. This combination has no moved onto a phase II study with a primary endpoint of response rate.
SELECTED
LANGUAGE


Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

The anti-HER2 monoclonal antibody, margetuximab, is being studied in combination with pembrolizumab as a treatment for patients with advanced HER2-positive GEJ or gastric adenocarcinoma. Margetuximab has an optimized Fc domain to increase affinity for activating CD16A-F allele, says Catenacci, and preclinical data suggests activity in HER2-positive patients. Additionally, pembrolizumab has demonstrated durable responses in this population.

In a phase Ib study assessing the safety and toxicity of the combination, there were no unforeseen events of toxicities. Catenacci says that most of the toxicities were attributed to the anti–PD-1 agent pembrolizumab. This combination has no moved onto a phase II study with a primary endpoint of response rate.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Publication Bottom Border
Border Publication
x